A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

← catalyst calendar

NCT06542874

Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.

Phase

Phase 2

Status

Completed

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

448actual

Sites

137

Countries

Bulgaria, Croatia, Germany +8

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-08-07

actual

When the study began enrolling

Primary completion

2025-10-01

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2025-10-24

actual

The whole study's end, after follow-up

First posted

2024-08-07

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Type 2 Diabetes (T2D)

Interventions

Drug: NNC0487-0111 subcutanous
Drug: Placebo (NNC0487-0111 subcutanous)
Drug: NNC0487-0111 oral
Drug: Placebo (NNC0487-0111 oral)

Primary outcome

what the primary-completion date above is the date OF

Change in HbA1c

measured From baseline (week 0) to end of treatment (week 36)

Publications

PMID 42532080 — linked by the registry
PMID 42532079 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed